Welcome to our dedicated page for Natera news (Ticker: NTRA), a resource for investors and traders seeking the latest updates and insights on Natera stock.
Natera Inc (NASDAQ: NTRA) delivers cutting-edge genetic testing solutions through its proprietary molecular diagnostics platform. This news hub provides investors and healthcare professionals with timely updates on corporate developments, clinical research breakthroughs, and regulatory milestones.
Access official press releases alongside curated analysis of NTRA's innovations in non-invasive prenatal testing, oncology diagnostics, and transplant monitoring. Our repository tracks critical updates including quarterly earnings, partnership announcements, and peer-reviewed study publications.
Key coverage areas include advancements in circulating tumor DNA detection, expansions in reproductive health screening, and financial performance metrics. Bookmark this page to monitor how Natera's bioinformatics expertise continues influencing precision medicine across 150+ countries.
Natera, Inc. (NASDAQ: NTRA) has partnered with Tesis Labs to enhance prenatal genetic testing services across the U.S., including Texas, Colorado, and Arizona. This collaboration aims to improve access to genetic testing for over 4 million pregnancies annually, leveraging Tesis’s advanced laboratory capabilities in Lafayette, Colorado. Both companies emphasize the importance of early screening for informed healthcare decisions, thereby broadening Tesis's testing offerings and strategically positioning Natera in a growing market.
Natera, Inc. (NASDAQ: NTRA) has received two new Breakthrough Device Designations from the FDA for its Signatera molecular residual disease (MRD) test. These designations facilitate the development of Signatera as a companion diagnostic for two cancer therapies, adding to the existing 2019 designation. Over $65 million in contracts have been signed in the past year for Phase III clinical trials involving Signatera. This reflects Natera's commitment to advancing precision oncology and improving cancer treatment outcomes.
Natera, Inc. (NASDAQ: NTRA) announced the initiation of a phase III clinical trial using its Signatera test as a companion diagnostic for muscle-invasive urothelial carcinoma (MIUC) patients. This study, sponsored by Genentech, aims to evaluate the efficacy of atezolizumab in MRD-positive patients post-surgery. The trial seeks to enroll approximately 500 MRD-positive patients, with disease-free survival as the primary endpoint. Previous studies indicated significant benefits for MRD-positive patients treated with atezolizumab, highlighting the potential of Signatera in addressing unmet needs in bladder cancer treatment.
Natera, Inc. (NASDAQ: NTRA) reported strong financial results for Q4 2020, with total revenues of $112.4 million, a 35.1% increase from Q4 2019. Product revenues surged 43%, and tests processed reached approximately 295,000. For the full year, revenues climbed 29.3% to $391 million, surpassing guidance. The company announced successful clinical trial results and expanded its oncology portfolio. Despite operating expenses rising to $126.5 million, resulting in a net loss of $76.4 million for Q4 2020, the outlook for 2021 is optimistic with expected revenues between $500 million and $525 million.
Natera, a leader in cell-free DNA testing, will present at the Cowen 41st Annual Health Care Conference on March 2, 2021, at 11:10 a.m. PT (2:10 p.m. ET). CFO Mike Brophy will discuss recent company activities and engage in a Q&A session. The live webcast and archived presentation will be accessible via investor.natera.com. Natera aims to revolutionize disease management with a focus on women's health, oncology, and organ health, operating ISO-certified labs in California and Texas.
Natera, a leader in cell-free DNA testing, will announce its fourth quarter and year-end financial results on February 25, 2021, after market close. A conference call will follow at 1:30 p.m. PT to discuss the results, business activities, and outlook. Investors can join via live dial-in or through a webcast available on their website. Natera aims to revolutionize disease management with its innovative testing solutions, focusing on women's health, oncology, and organ health.
Personalis (Nasdaq: PSNL) and Natera (Nasdaq: NTRA) have launched a partnership to advance personalized oncology. Their collaboration combines Personalis’ NeXT tumor profiling with Natera’s Signatera ctDNA platform for monitoring treatment and assessing molecular residual disease. Natera will validate Signatera assays using Personalis' data and handle commercialization. This non-exclusive agreement aims to enhance the integration of these technologies in clinical and research applications, expanding patient access to innovative cancer monitoring solutions.
Natera, Inc. (Nasdaq: NTRA) and Personalis, Inc. (Nasdaq: PSNL) have announced a partnership aimed at enhancing personalized oncology. This non-exclusive agreement integrates Personalis' NeXT tumor profiling products with Natera's Signatera ctDNA platform for monitoring treatment and assessing molecular residual disease (MRD). Natera will validate Signatera assays using tumor and normal exome data from Personalis and take charge of commercialization. The collaboration aims to improve availability and reliability of advanced cancer diagnostics.
Natera, Inc. (NASDAQ: NTRA), a leader in cell-free DNA testing, announced participation in two significant conferences. Alexey Aleshin, MD, will join a panel at the BTIG Virtual MedTech Conference on February 18, 2021, at 10:00 a.m. PT. Additionally, Steve Chapman, CEO, and Mike Brophy, CFO, will engage in a fireside chat at the 10th Annual SVB Leerink Global Healthcare Conference on February 26, 2021, at 11:20 a.m. PT. Live webcasts will be available at investor.natera.com.
Natera, Inc. (NASDAQ: NTRA) presented promising results from its SMART study at the SMFM 41st Annual Pregnancy Meeting. This study, the largest of its kind in non-invasive prenatal testing (NIPT), confirmed the market-leading accuracy of Natera's Panorama test. Key findings include 99% sensitivity and over 99.95% specificity for trisomy 21, along with enhanced performance from the new Panorama AI algorithm, which reduced the no-call rate to 1.5%. The study’s results further solidify Panorama's status as the most extensively researched NIPT available.
